Sarah Scagliarini, MD (@sscagliarini_) 's Twitter Profile
Sarah Scagliarini, MD

@sscagliarini_

Medical Oncologist at AORN Cardarelli in Naples #GU cancers #RCC #kidneycancer #prostatecancer #bladdercancer #UC #Immunotherapy

ID: 1849810398330912768

calendar_today25-10-2024 13:49:46

298 Tweet

147 Followers

332 Following

International Urology Cancer Summit (@urologysummit) 's Twitter Profile Photo

Oral at #IUCS25: In MIUC, maintaining Relative Dose Intensity (RDI) ≥80% of neoadjuvant platinum chemo 📈 significantly boosts pCR rates. Strong evidence for the role of treatment intensity before cystectomy Giuseppe Neola OncoAlert #urology #cancer

Oral at #IUCS25:

In MIUC, maintaining Relative Dose Intensity (RDI) ≥80% of neoadjuvant platinum chemo 📈 significantly boosts pCR rates. Strong evidence for the role of treatment intensity before cystectomy 

<a href="/NeolaGiuseppe/">Giuseppe Neola</a> <a href="/OncoAlert/">OncoAlert</a> 

#urology #cancer
Armani (@armani) 's Twitter Profile Photo

Milan, 4 September 2025 – With infinite sorrow, the Armani Group announces the passing of its creator, founder, and tireless driving force: Giorgio Armani. Il Signor Armani, as he was always respectfully and admiringly called by employees and collaborators, passed away

Milan, 4 September 2025 – With infinite sorrow, the Armani Group announces the passing of its creator, founder, and tireless driving force: Giorgio Armani.

Il Signor Armani, as he was always respectfully and admiringly called by employees and collaborators, passed away
OncoAlert (@oncoalert) 's Twitter Profile Photo

A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹 ⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways ✅ Feasible in selected patients, with potential for long-term disease control ✅ Reduced toxicity burden vs continuous therapy 📊 Stronger evidence with

A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹 

⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with
World Radiotherapy Awareness Day (@worldrtday) 's Twitter Profile Photo

We chose the theme of One Voice for our inaugural year of World Radiotherapy Awareness Day because we want everyone working in the field to join together and speak up for the millions around the world who do not have access to safe, high-quality radiotherapy.

We chose the theme of One Voice for our inaugural year of World Radiotherapy Awareness Day because we want everyone working in the field to join together and speak up for the millions around the world who do not have access to safe, high-quality radiotherapy.
The Lancet Oncology (@thelancetoncol) 's Twitter Profile Photo

🔴Online today: Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell #renalcellcarcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial Chad Tang, MD thelancet.com/journals/lanon…

🔴Online today: Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell #renalcellcarcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial <a href="/ChadTangMD/">Chad Tang, MD</a> 

thelancet.com/journals/lanon…
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Loved the wonderful talk by Laurence Albiges at #IUCS25 👉 On biomarkers in #kidneycancer 👉 tumor PD-L1 expression, blood based KIM-1 and MAdCAM-1, patient selection for microbiome Rx, and more👉new era of biomarker investigation in RCC OncoAlert KidneyCAN UroToday.com

Loved the wonderful talk by <a href="/AlbigesL/">Laurence Albiges</a> at #IUCS25 👉 On biomarkers in #kidneycancer 👉 tumor PD-L1 expression, blood based KIM-1 and MAdCAM-1, patient selection for microbiome Rx, and more👉new era of biomarker investigation in RCC <a href="/OncoAlert/">OncoAlert</a> <a href="/kidneycan/">KidneyCAN</a> <a href="/urotoday/">UroToday.com</a>
International Urology Cancer Summit (@urologysummit) 's Twitter Profile Photo

Oral at #IUCS25: Updated Meet-URO score in mRCC outperforms IMDC in prognostic accuracy for OS in 1st-line IO combinations (n=1418, 31 centers). Supports clinical use & trial stratification, aiding personalized treatment pas_rescigno OncoAlert #mRCC #Immunotherapy #Oncology

Oral at #IUCS25:
Updated Meet-URO score in mRCC outperforms IMDC in prognostic accuracy for OS in 1st-line IO combinations (n=1418, 31 centers). 
Supports clinical use &amp; trial stratification, aiding personalized treatment

<a href="/PasRescigno/">pas_rescigno</a> <a href="/OncoAlert/">OncoAlert</a> 

#mRCC #Immunotherapy #Oncology
Cristiane D Bergerot (@crisbergerot) 's Twitter Profile Photo

Did you know comprehensive geriatric assessment can predict treatment tolerance & outcomes in older adults with cancer? New ASCO guideline JCO Global Oncology Enrique Soto ascopubs.org/doi/full/10.12…

Did you know comprehensive geriatric assessment can predict treatment tolerance &amp; outcomes in older adults with cancer? 

New <a href="/ASCO/">ASCO</a> guideline <a href="/JCOGO_ASCO/">JCO Global Oncology</a> 
<a href="/EnriqueSoto8/">Enrique Soto</a> 

ascopubs.org/doi/full/10.12…
Uromigos (@uromigos) 's Twitter Profile Photo

🎯 Announcing the Eurasia team for the Uromigos cup 🏆 November 7th and 8th - Nashville with Cristina Suarez. Current score is Eurasia =1 vs North America= 0 from the 🎯 darts competition!! Sumanta K. Pal, MD, FASCO & Americas got 51 ❤️ ‘likes’ in 10 days. Can Eurasia get more??

Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

Phase 2 trial: In oligometastatic clear-cell RCC, serial metastasis-directed therapy (no systemic Tx) achieved median 34 mo systemic therapy-free survival & 17.7 mo PFS with low grade 3–4 toxicity. A promising option for select pts. 🔎To finish discussion need to 3 arms phase-3

Phase 2 trial: In oligometastatic clear-cell RCC, serial metastasis-directed therapy (no systemic Tx) achieved median 34 mo systemic therapy-free survival &amp; 17.7 mo PFS with low grade 3–4 toxicity. A promising option for select pts.

🔎To finish discussion need to 3 arms phase-3
Cristiane D Bergerot (@crisbergerot) 's Twitter Profile Photo

🗣️ Words matter #WCLC25 The new IASLC Language Guide offers best practices for presentations and abstracts, encouraging thoughtful, accurate, and stigma-free communication in lung cancer 🔗 iaslc.org/file/11932/dow… Jill Feldman Narjust Florez, MD, FASCO

🗣️ Words matter #WCLC25 
The new <a href="/IASLC/">IASLC</a> Language Guide offers best practices for presentations and abstracts, encouraging thoughtful, accurate, and stigma-free communication in lung cancer

🔗 iaslc.org/file/11932/dow… 

<a href="/jillfeldman4/">Jill Feldman</a> <a href="/NarjustFlorezMD/">Narjust Florez, MD, FASCO</a>
AttardLab (@attardlab) 's Twitter Profile Photo

ICYMI 👇 our latest study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer sciencedirect.com/science/articl… Please share!

Tom Powles (@tompowles1) 's Twitter Profile Photo

Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.

Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.
Sarah Scagliarini, MD (@sscagliarini_) 's Twitter Profile Photo

🧽 Amazing refresher this morning in my car 🚗 with Joshua Meeks at Uromigos podcast about emerging and evolving NMIBC space ( Single arm, endpoints, CIS, ODAC & the rest 🌍 …) with Tom Powles & Brian Rini, MD 💡 after the news 📢!! x.com/uromigos/statu…

Carlo Verdelli (@carloverdelli) 's Twitter Profile Photo

Droni di Mosca in Polonia. Dice qualcosa? Mattarella: “Rischiamo il baratro come nel 1914”. Allora cominciò la Prima guerra mondiale. Ove mai, non sarebbe la Terza guerra mondiale ma l’ultima. La politica italiana, governo e opposizione, è molto preoccupata: delle Regionali.